Toggle Main Menu Toggle Search

ePrints

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: The malt study

Lookup NU author(s): Professor Ian McKeith

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week treatment period. Methods. Six hundred and five patients were randomized to placebo (n = 208), a 40/50 mg dose (40 or 50 mg by weight; n = 200) or a 60/80 mg dose (60 or 80 mg by weight; n = 197) metrifonate. Patients randomized to receive metrifonate were administered a once-daily loading dose of 80 or 120 mg based on weight for 2 weeks, followed by the relevant maintenance dose for 24 weeks. Four main clinical domains of AD were assessed: cognition (ADAS-cog and MMSE), psychiatric and behavioural symptoms (ADAS-noncog and NPI), instrumental and basic activities of daily living (DAD) and global functioning (CIBIC-plus, CIBIS-plus and GDS). Results. ADAS-cog performance was significantly improved in the 60/80 mg and 40/50 mg dose groups, compared with placebo, in the intention-to-treat (ITT) population. In addition, statistically significant treatment differences were demonstrated between the 60/80 mg dose group and placebo on MMSE, ADAS-noncog, the NPI subitems of hallucinations and apathy, DAD, CIBIC-plus, CIBIS-plus and the GDS, The performance of the 40/50 mg dose group was also significantly superior to placebo on the CIBIS-plus and the NPI subitem aberrant motor behaviour. Conclusions. Metrifonate significantly improved a wide range of symptoms across all four clinical domains of AD in a dose-dependent manner, and was safe and well tolerated at both doses studied. Copyright (C) 1999 John Wiley & Sons, Ltd.


Publication metadata

Author(s): McKeith I; Dubois B; Orgogozo JM; Collins O; Meulien D; Malt Study Grp

Publication type: Article

Publication status: Published

Journal: International Journal of Geriatric Psychiatry

Year: 1999

Volume: 14

Issue: 11

Pages: 973-982

Print publication date: 01/11/1999

ISSN (print): 0885-6230

ISSN (electronic): 1099-1166

Publisher: John Wiley & Sons Ltd.

URL: http://dx.doi.org/10.1002/(SICI)1099-1166(199911)14:11<973::AID-GPS58>3.0.CO;2-U

DOI: 10.1002/(SICI)1099-1166(199911)14:11<973::AID-GPS58>3.0.CO;2-U


Altmetrics

Altmetrics provided by Altmetric


Actions

    Link to this publication


Share